CARTITUDE-4: the first phase 3 results
Prof. Michel Delforge, a haematologist at UZ Leuven, provided a comprehensive summary of the current state of multiple myeloma treatment. He also shared the initial findings from the CARTITUDE-4 study’s phase 3 results, which compared cilta-cel to standard of care for patients with lenalidomide-refractory multiple myeloma.
With the educational support of:
